<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管高季刊</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230827060719&amp;utm_medium=rss&amp;utm_campaign=pub med-2&amp;utm_source=Chrome&amp;v=2.17.9.post6+86293ac&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U- NVu8003KrCpq8yLQC -<description>心血管高季刊：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230827060719&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;v=2.17.9.post6+86293ac&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 8 月 27 日星期日 10:07:19 +0000</lastbuilddate><pubDate> Sat, 26 Aug 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>血小板生成素-MPL受体复合物的结构是造血偏向的蓝图</title><link/>https://pubmed.ncbi.nlm.nih.gov/37633268/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230827060719&amp;v=2.17.9.post6+86293ac<description>血小板生成素（THPO 或 TPO）是造血干细胞（HSC）维持和巨核细胞分化的重要细胞因子。在这里，我们报道了细胞外 TPO-TPO 受体（TpoR 或 MPL）信号复合物的 3.4 Å 分辨率冷冻电镜结构，揭示了同二聚体 MPL 激活的基础，并为遗传功能丧失性血小板减少症突变提供结构合理化。该结构指导 TPO 变体 (TPO^(mod)) 的工程设计，具有... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 8 月 22 日：S0092-8674(23)00852-8.doi: 10.1016/j.cell.2023.07.037.打印前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">血小板生成素（THPO 或 TPO）是造血干细胞（HSC）维持和巨核细胞分化的重要细胞因子。在这里，我们报道了细胞外 TPO-TPO 受体（TpoR 或 MPL）信号复合物的 3.4 Å 分辨率冷冻电镜结构，揭示了该结构指导了 TPO 变体 (TPO <sup>mod</sup> ) 的工程设计，具有从中性拮抗剂到部分激动剂和超级激动剂等一系列信号活动。部分激动剂 TPO <sup>mod</sup>将 JAK/STAT 与 ERK/AKT/CREB ​​激活解耦，驱动巨核细胞生成和血小板生成的偏差，而不会引起小鼠体内 HSC 的显着扩增，并在体外显示出对人类 HSC 的卓越维持。TPO 的主要作用，凸显了其潜在效用TPO <sup>mod</sup>在血液学研究和临床HSC移植中的应用。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37633268/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827060719&v=2.17.9.post6+86293ac">37633268</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.07.037>10.1016/j.cell.2023.07.037</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37633268</guid><pubDate> Sat, 26 Aug 2023 06:00:00 -0400</pubDate><dc:creator>堤直隆</dc:creator><dc:creator>扎赫拉·马苏米</dc:creator><dc:creator>苏菲·C·詹姆斯</dc:creator><dc:creator>朱莉·塔克</dc:creator><dc:creator>豪克·温克尔曼</dc:creator><dc:creator>威廉·格雷</dc:creator><dc:creator>洛拉·K·皮克顿</dc:creator><dc:creator>露西·莫斯</dc:creator><dc:creator>史蒂文·C·威尔逊</dc:creator><dc:creator>纳撒内尔·卡夫尼</dc:creator><dc:creator>——凯文·M·裘德</dc:creator><dc:creator>科尼利厄斯·加蒂</dc:creator><dc:creator>雅各布·皮勒</dc:creator><dc:creator>伊恩·希区柯克</dc:creator><dc:creator>K克里斯托弗·加西亚</dc:creator><dc:date>2023-08-26</dc:date><dc:source>细胞</dc:source><dc:title>血小板生成素-MPL受体复合物的结构是造血偏向的蓝图</dc:title><dc:identifier>下午：37633268</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.07.037</dc:identifier></item><item><title> PINK1、Keap1 和 Rtnl1 调节发育过程中内质网的选择性清除</title><link/>https://pubmed.ncbi.nlm.nih.gov/37633267/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230827060719&amp;v=2.17.9.post6+86293ac<description>通过自噬选择性清除细胞器，包括内质网 (ER) 和线粒体，在细胞健康中发挥着重要作用。在这里，我们描述了通过自噬进行的发育程序选择性 ER 清除。我们表明，帕金森病相关的 PINK1 以及 Atl 、Rtnl1 和 Trp1 受体，通过自噬调节 ER 清除。E3 泛素连接酶 Parkin 在 PINK1 下游发挥作用，是线粒体清除所必需的，同时在... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 8 月 21 日：S0092-8674(23)00862-0. doi: 10.1016/j.cell.2023.08.008. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">通过自噬选择性清除细胞器，包括内质网 (ER) 和线粒体，在细胞健康中发挥着重要作用。在这里，我们描述了通过自噬进行的发育程序选择性 ER 清除。我们表明，帕金森病相关的 PINK1 以及 Atl 、Rtnl1 和 Trp1 受体，通过自噬调节 ER 清除。E3 泛素连接酶 Parkin 在 PINK1 下游发挥作用，是线粒体清除所必需的，而在内质网清除中具有相反的功能。PINK1 通过影响 Rtnl1 和 Atl 来调节 ER 清除。PINK1 调节ER 吞噬受体 Rtnl1 的 Keap1 定位和 Keap1 依赖性泛素化的变化以促进 ER 清除。因此，PINK1 通过影响决定哪种细胞器的 Keap1 和 Parkin 依赖性底物泛素化的平衡来调节 ER 和线粒体的选择性清除通过自噬被去除。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37633267/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827060719&v=2.17.9.post6+86293ac">37633267</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.08.008>10.1016/j.cell.2023.08.008</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37633267</guid><pubDate> Sat, 26 Aug 2023 06:00:00 -0400</pubDate><dc:creator>王若曦</dc:creator><dc:creator>蒂娜·M·福蒂尔</dc:creator><dc:creator>飞柴</dc:creator><dc:creator>苗光彦</dc:creator><dc:creator>詹姆斯·L·沉</dc:creator><dc:creator>卢卡斯·雷斯特雷波</dc:creator><dc:creator>杰罗米·J·迪贾科莫</dc:creator><dc:creator>帕纳吉奥蒂斯·维伦萨斯</dc:creator><dc:creator>埃里克·巴赫里克</dc:creator><dc:date>2023-08-26</dc:date><dc:source>细胞</dc:source><dc:title>PINK1、Keap1 和 Rtnl1 调节发育过程中内质网的选择性清除</dc:title><dc:identifier>下午：37633267</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.008</dc:identifier></item><item><title>循环二肽基肽酶 3 - 改善心源性休克预后的特定治疗的新希望？</title><link/> https://pubmed.ncbi.nlm.nih.gov/37632844/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230827060719&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 26 日：ehad568。doi：10.1093/eurheartj/ehad568。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37632844/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827060719&v=2.17.9.post6+86293ac">37632844</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad568>10.1093/eurheartj/ehad568</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37632844</guid><pubDate> Sat, 26 Aug 2023 06:00:00 -0400</pubDate><dc:creator>珍妮·波斯</dc:creator><dc:creator>佩特拉·巴特纳</dc:creator><dc:creator>霍尔格·蒂勒</dc:creator><dc:date>2023-08-26</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>循环二肽基肽酶 3 - 改善心源性休克预后的特定治疗的新希望？</dc:title><dc:identifier>下午：37632844</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad568</dc:identifier></item><item><title>左冠状动脉主干疾病的低手术风险患者的血运重建：重新审视证据</title><link/>https://pubmed.ncbi.nlm.nih.gov/37632758/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230827060719&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 26 日：ehad506。doi：10.1093/eurheartj/ehad506。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37632758/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827060719&v=2.17.9.post6+86293ac">37632758</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad506>10.1093/eurheartj/ehad506</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37632758</guid><pubDate> Sat, 26 Aug 2023 06:00:00 -0400</pubDate><dc:creator>科林·拜金特</dc:creator><dc:creator>拉斐尔·萨达巴</dc:creator><dc:date>2023-08-26</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>左冠状动脉主干疾病的低手术风险患者的血运重建：重新审视证据</dc:title><dc:identifier>下午：37632758</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad506</dc:identifier></item><item><title> 2022 年 ESC/EACTS 联合审查 2018 年关于低手术风险且解剖结构适合 PCI 或 CABG 的患者左主干冠状动脉疾病血运重建的指南建议</title><link/>https://pubmed.ncbi.nlm.nih.gov/37632756/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230827060719&amp;v=2.17.9.post6+86293ac<description> 2021 年 10 月，欧洲心脏病学会 (ESC) 和欧洲心胸外科协会 (EACTS) 共同同意成立一个工作组 (TF)，以审查 2018 年 ESC/EACTS 心肌血运重建指南的建议。 SYNTAX 评分为中低 (0-32) 的左主干 (LM) 疾病患者。在此之前，EACTS 于 2019 年撤销了对之前关于 LM 疾病管理建议的支持…… </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 26 日：ehad476。doi：10.1093/eurheartj/ehad476。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> 2021 年 10 月，欧洲心脏病学会 (ESC) 和欧洲心胸外科协会 (EACTS) 共同同意成立一个工作组 (TF)，以审查 2018 年 ESC/EACTS 心肌血运重建指南的建议。 SYNTAX 评分为中低 (0-32) 的左主干 (LM) 疾病患者。在此之前，EACTS 于 2019 年撤销了对之前指南中有关 LM 疾病管理的建议的支持。TF被要求审查自 2018 年指南以来的所有新相关数据，包括四项随机试验的更新汇总数据，这些试验比较了 LM 疾病患者的经皮冠状动脉介入治疗 (PCI) 与药物洗脱支架与冠状动脉旁路移植术 (CABG)。 TF 的工作总结；其中包括针对 LM 疾病接受心肌血运重建的患者选择血运重建方式的最新建议。预测手术死亡率后，TF 得出结论，根据患者偏好、可用专业知识和当地操作者数量，两种治疗方案在临床上都是合理的。使用 CABG 进行血运重建的建议为 I 类，证据级别为 A。PCI 的建议为 IIa 类，证据级别 A。 TF 认识到与 LM 疾病患者血运重建相关的知识存在几个重要差距，并认识到四项随机试验的汇总数据仍然仅足以排除死亡率的巨大差异。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37632756/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827060719&v=2.17.9.post6+86293ac">37632756</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad476>10.1093/eurheartj/ehad476</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37632756</guid><pubDate> Sat, 26 Aug 2023 06:00:00 -0400</pubDate><dc:creator> ——罗伯特·A·伯恩</dc:creator><dc:creator>史蒂芬·弗雷姆斯</dc:creator><dc:creator>达维德·卡波丹诺</dc:creator><dc:creator>马丁·切尔尼更多</dc:creator><dc:creator>托斯顿·多恩斯特</dc:creator><dc:creator>- 乔纳森·R·恩伯森</dc:creator><dc:creator>福尔克马尔·法尔克</dc:creator><dc:creator>马里奥·高迪诺</dc:creator><dc:creator>约翰·JV·麦克默里</dc:creator><dc:creator>罗克珊娜·迈赫兰</dc:creator><dc:creator>米兰·米洛耶维奇</dc:creator><dc:creator>米格尔·索萨·乌瓦</dc:creator><dc:date>2023-08-26</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>2022 年 ESC/EACTS 联合审查 2018 年关于低手术风险且解剖结构适合 PCI 或 CABG 的患者左主干冠状动脉疾病血运重建的指南建议</dc:title><dc:identifier>下午：37632756</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad476</dc:identifier></item><item><title>二肽基肽酶 3 血浆水平可预测急性冠脉综合征的心源性休克和死亡率</title><link/>https://pubmed.ncbi.nlm.nih.gov/37632743/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230827060719&amp;v=2.17.9.post6+86293ac<description>结论：本研究确定 cDPP3 是 CS 和 ACS 患者死亡率增加的新标志物。循环 DPP3 提供了既定风险因素之外的预后信息，并改善了早期风险评估。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 26 日：ehad545。doi：10.1093/eurheartj/ehad545。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：二肽基肽酶 3 (DPP3) 是一种参与血管紧张素 II 降解的蛋白酶，它会扰乱外周血压调节并损害左心室功能。导致急性冠脉综合征 (ACS) 患者的死亡率。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：对前瞻性纳入多中心 SPUM-ACS 研究的 ACS 患者 (n = 4787) 进行基线和就诊后 12-24 小时的血浆 cDPP3 水平评估。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：当考虑到包括 ORBI 风险评分在内的既定风险因素时，循环 DPP3 水平与院内 CS 相关（每增加 log-2，风险比 [HR] 1.38，95% 置信区间 [CI] 1.05-1.82，P =高 cDPP3 是 30 天（HR 1.87，95% CI 1.36-2.58，P &lt; 0.001）和 1 年（HR 1.61，95% CI 1.28-2.02，P &lt; 0.001）调整后死亡率的独立预测因子。危险因素和GRACE 2.0评分。与正常范围内的值相比，12-24小时持续升高的cDPP3水平与30天死亡风险增加13.4倍相关（HR 13.42，95% CI 4.86-37.09） ..，P &lt; 0.001），1 年死亡风险增加 5.8 倍（HR 5.79，95% CI 2.70-12.42，P &lt; 0.001）。不同患者亚组的结果一致。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：本研究确定 cDPP3 是 CS 和 ACS 患者死亡率增加的新标志物。循环 DPP3 提供了既定风险因素之外的预后信息，并改善了早期风险评估。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37632743/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827060719&v=2.17.9.post6+86293ac">37632743</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad545>10.1093/eurheartj/ehad545</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37632743</guid><pubDate> Sat, 26 Aug 2023 06:00:00 -0400</pubDate><dc:creator>弗洛里安·温兹尔</dc:creator><dc:creator>弗朗西斯科·布鲁诺</dc:creator><dc:creator>西蒙·克拉勒</dc:creator><dc:creator>罗兰·克林根伯格</dc:creator><dc:creator>亚历山大·艾哈迈多夫</dc:creator><dc:creator>斯特凡诺·米尼斯特里尼</dc:creator><dc:creator>卡琳桑托斯</dc:creator><dc:creator>康斯坦丁·戈德利</dc:creator><dc:creator>朱莉娅·戈德利</dc:creator><dc:creator>大卫·尼德塞尔</dc:creator><dc:creator>罗伯特·曼卡</dc:creator><dc:creator>安德烈亚斯·伯格曼</dc:creator><dc:creator>乔瓦尼·G·卡米奇</dc:creator><dc:creator>阿诺德·冯·埃卡斯坦</dc:creator><dc:creator>芭芭拉·斯塔利</dc:creator><dc:creator>奥利维尔·穆勒</dc:creator><dc:creator>马可·罗菲</dc:creator><dc:creator>洛伦兹·拉贝尔</dc:creator><dc:creator>托马斯·F·卢舍尔</dc:creator><dc:date>2023-08-26</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>二肽基肽酶 3 血浆水平可预测急性冠脉综合征的心源性休克和死亡率</dc:title><dc:identifier>下午：37632743</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad545</dc:identifier></item><item><title>经导管二尖瓣边对边修复术之前的心力衰竭药物治疗：STS/ACC 经导管瓣膜治疗登记处</title><link/>https://pubmed.ncbi.nlm.nih.gov/37632738/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230827060719&amp;v=2.17.9.post6+86293ac<description>结论：在美国全国登记处，接受 MTEER 治疗 FMR 的 LVEF &lt;50% 的患者中，有不到五分之一的患者接受了全面的 GDMT，不同地点之间差异很大。与无/单一治疗相比，MTEER 之前的三联和双联治疗是独立的与干预后一年死亡或 HFH 风险降低相关。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 26 日：ehad584。doi：10.1093/eurheartj/ehad584。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：对于心力衰竭（HF）和严重功能性二尖瓣反流（FMR）患者，建议在二尖瓣经导管边对边修复术（MTEER）之前进行指南指导的药物治疗（GDMT）。 GDMT 在临床实践中的应用尚不清楚。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：确定了胸外科医生协会/美国心脏病学会经导管瓣膜治疗登记处于 2019 年 7 月 23 日至 2022 年 3 月 31 日接受 MTEER 治疗 FMR 的左心室射血分数 (LVEF) &lt; 50% 的患者。构建 Cox 比例风险模型来评估 MTEER 治疗前（无/单一、双重或三重治疗）与一年死亡率或心衰住院 (HFH) 风险之间的关联。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在449个地点的4,199名患者中，β受体阻滞剂、血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂、盐皮质激素受体拮抗剂和血管紧张素受体脑啡肽酶抑制剂的使用率分别为85.1%、44.4%、28.6%和19.9%​​在干预前接受三联治疗的患者比例为 19.2%，双重治疗为 38.2%，单一治疗为 36.0%，6.5% 未接受 GDMT。观察到干预前接受三联治疗的患者比例存在显着的中心水平差异（0 –61%；调整中位比值比 1.48 [95% 置信区间 (CI) 1.25–3.88]；P &lt; 0.001)。在符合一年随访条件的患者中（n = 2,014；341 个研究中心），复合率。接受三联治疗的患者的一年死亡率或 HFH 的比例最低 (23.1%)，而与双联治疗 (24.8%)、单联治疗 (35.7%) 和无治疗 (41.1%) 治疗的患者相比，一年死亡率或 HFH 最低（组间比较 P &lt; 0.01）。考虑到相关的临床特征后，与 MTEER 相比，在 MTEER 之前接受三联疗法（调整后的风险比 [aHR] 0.73，95% CI 0.55-0.97）和双联疗法（aHR 0.69，95% CI 0.56-0.86）的患者风险较低无/单一治疗。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在美国全国登记处，接受 MTEER 治疗 FMR 的 LVEF &lt;50% 的患者中，有不到五分之一的患者接受了全面的 GDMT，不同地点之间差异很大。与无/单一治疗相比，MTEER 之前的三联和双联治疗是独立的与干预后一年死亡或 HFH 风险降低相关。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37632738/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827060719&v=2.17.9.post6+86293ac">37632738</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad584>10.1093/eurheartj/ehad584</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37632738</guid><pubDate> Sat, 26 Aug 2023 06:00:00 -0400</pubDate><dc:creator>阿努博德·S·瓦尔什尼</dc:creator><dc:creator>米洛尼·沙阿</dc:creator><dc:creator>斯里坎特·韦穆拉帕利</dc:creator><dc:creator>安杰伊·科辛斯基</dc:creator><dc:creator>安基特·巴特</dc:creator><dc:creator>亚历山大·桑杜</dc:creator><dc:creator>萨米尔·赫吉</dc:creator><dc:creator>艾尔西利亚·M·德菲利皮斯</dc:creator><dc:creator>皮纳克·B·沙阿</dc:creator><dc:creator>莫娜·菲扎特</dc:creator><dc:creator>帕特里克·T·奥加拉</dc:creator><dc:creator>迪帕克·巴特</dc:creator><dc:creator>金子刚</dc:creator><dc:creator>——迈克尔·M·吉弗茨</dc:creator><dc:creator>穆蒂亚·瓦杜加纳坦</dc:creator><dc:date>2023-08-26</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>经导管二尖瓣边对边修复术之前的心力衰竭药物治疗：STS/ACC 经导管瓣膜治疗登记处</dc:title><dc:identifier>下午：37632738</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad584</dc:identifier></item><item><title>急性冠脉综合征后脂蛋白(a)浓度与心血管事件风险的关系：三种测试的比较</title><link/>https://pubmed.ncbi.nlm.nih.gov/37632469/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230827060719&amp;v=2.17.9.post6+86293ac<description>背景：脂蛋白 (a) 是心血管事件的危险因素，会影响 pcsk9 抑制剂 (pcsk9i) 的益处。脂蛋白 (a) 浓度可以通过报告质量或摩尔浓度的免疫测定法或采用质谱法的参考测量系统进行测量。高危队列中脂蛋白 (a) 浓度和心血管事件在不同脂蛋白 (a) 方法中的差异尚不清楚。我们比较了...的预后和预测价值。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 8 月 26 日。doi：10.1161/CIRCULATIONAHA.123.066398。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>背景：</b>脂蛋白 (a) 是心血管事件的危险因素，会影响 pcsk9 抑制剂 (pcsk9i) 的益处。脂蛋白 (a) 浓度可以通过报告质量或摩尔浓度的免疫测定法或采用质谱法的参考测量系统进行测量。高危队列中脂蛋白(a) 浓度和心血管事件因脂蛋白(a) 方法而异尚不清楚。我们比较了这些类型的脂蛋白(a) 测试对主要不良心血管事件(mace) 的预后和预测价值<b>。方法：</b>奥德赛结果试验将 pcsk9i alirocumab 与安慰剂在近期急性冠状动脉综合征 (acs) 患者中进行了比较。我们根据西门子测量的基线脂蛋白 (a) 浓度，比较了安慰剂组中的梅斯风险和 alirocumab 降低的梅斯风险。乳胶比浊免疫分析（ia-mass，mg/dl）、罗氏 tina-quant® 比浊免疫分析（ia-molar，nmol/l）和非商业质谱测试（ms，nmol/l）。 a) 将值转换为百分位数以进行比较建模。自然三次样条估计基线脂蛋白（a）与每个治疗<b>组的结果之间的连续关系。还确定了每个测定定义的基线脂蛋白（a）四分位数的事件率。：</b>在所有 3 项测试结果的 11,970 名试验参与者中，基线中位 (q1, q3) 脂蛋白 (a) 浓度分别为 21.8 (6.9, 60.0) mg/dl、45.0 (13.2, 153.8) nmol/l 和 42.2 (14.3, 143.1) ) nmol/l 分别表示 ia-mass、ia-molar 和 ms。以及 ia-mass 和 ia-molar (r=0.972)。安慰剂组中脂蛋白 (a) 与梅斯风险的关系几乎相同测试的估计累积发生率在脂蛋白 (a) 百分位数上相差 ≤0.4%，并且在考虑 LDL-c 后，所有预测的预后都逐渐增强（所有样条 p≤0.0003）。三项测试中每一项的预测 alirocumab 治疗效果也几乎相同，估计的治疗风险比（小时）在各百分位数的测试之间差异≤0.07，并且在所有三项测试中，alirocumab 在较低百分位数上名义上相对风险降低较少。alirocumab 的绝对风险降低随着每次测试测量的脂蛋白（a）的增加而增加，<b>结论：</b>在近期患有 acs 的患者中，安慰剂组中的三项脂蛋白 (a) 测试对梅斯的预后相似，并可预测队列水平上 alirocumab 治疗后梅斯的减少。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37632469/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827060719&v=2.17.9.post6+86293ac">37632469</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066398>10.1161/CIRCULATIONAHA.123.066398</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37632469</guid><pubDate> Sat, 26 Aug 2023 06:00:00 -0400</pubDate><dc:creator>迈克尔·萨雷克</dc:creator><dc:creator>埃丝特·雷金德斯</dc:creator><dc:creator>J·沃特·朱克玛</dc:creator><dc:creator>迪帕克·巴特</dc:creator><dc:creator>维拉·比特纳</dc:creator><dc:creator>拉斐尔·迪亚兹更多</dc:creator><dc:creator>塞尔吉奥·法齐奥</dc:creator><dc:creator>吉纳维夫·加隆</dc:creator><dc:creator>肖恩·G·古德曼</dc:creator><dc:creator>——罗伯特·A·哈林顿</dc:creator><dc:creator>L蕾妮·鲁哈克</dc:creator><dc:creator>马库斯·施韦特费格</dc:creator><dc:creator>索蒂里奥斯·齐米卡斯</dc:creator><dc:creator>哈维·D·怀特</dc:creator><dc:creator>加布里埃尔·斯泰格博士</dc:creator><dc:creator>克里斯塔·科巴特</dc:creator><dc:creator>——格雷戈里·G·施瓦茨</dc:creator><dc:creator>奥德赛结果 研究人员</dc:creator><dc:date>2023-08-26</dc:date><dc:source>循环</dc:source><dc:title>急性冠脉综合征后脂蛋白(a)浓度与心血管事件风险的关系：三种测试的比较</dc:title><dc:identifier>下午：37632469</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.066398</dc:identifier></item><item><title> DELIVER 试验中射血分数轻度降低和保留的心力衰竭患者的门诊病情恶化</title><link/>https://pubmed.ncbi.nlm.nih.gov/37632455/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230827060719&amp;v=2.17.9.post6+86293ac<description>背景：住院治疗被认为是心力衰竭（HF）患者疾病轨迹中的前哨事件，但并非所有经历临床失代偿的患者最终都会住院治疗。门诊患者加强利尿剂治疗是常见的，以应对心力衰竭恶化的症状，但其预后和临床相关性，特别是在射血分数轻度降低或保留的心力衰竭患者中，尚不确定。方法：在对 DELIVER 的预先指定分析中... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 8 月 26 日。doi：10.1161/CIRCULATIONAHA.123.066506。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>背景：</b>住院治疗被认为是心力衰竭（HF）患者疾病轨迹中的前哨事件，但并非所有经历临床失代偿的患者最终都会住院治疗。门诊患者加强利尿剂治疗是常见的，以应对心力衰竭恶化的症状，但其预后<b>方法：</b>在 DELIVER 试验的这项<i>预先指定的</i>分析中，我们评估了各种非致命性心力衰竭恶化事件（需要住院治疗、紧急门诊就诊的事件）之间的关联需要静脉心力衰竭治疗和门诊口服利尿剂强化）以及随后的死亡率。我们进一步检查了达格列净对心血管死亡、心力衰竭住院、紧急心力衰竭就诊或门诊口服利尿剂强化的扩展复合终点的治疗效果<b>。</b>交付时，4,532 名患者 (72%) 没有经历心力衰竭恶化事件，而 789 名患者 (13%) 接受了门诊口服利尿剂强化治疗，86 名患者 (1%) 需要紧急心力衰竭就诊，585 名患者 (9%) 发生了心力衰竭住院治疗，271 名患者 (1%) 接受了心力衰竭住院治疗。 4%) 首次就诊时死于心血管原因。首次就诊表现为门诊口服利尿剂强化的患者随后的死亡率高于没有心衰恶化事件的患者 (4%) (10[8-12]/100py)。 [3-4] 每 100py)，但与紧急心力衰竭就诊后的后续死亡率相似 (10[6-18] 每 100py)。首次出现心力衰竭恶化而住院治疗的患者后续死亡率最高 (在判定的 DELIVER 主要终点（心血管死亡、心力衰竭住院或紧急心力衰竭就诊）中添加门诊强化利尿剂，使经历事件的患者总数从 1,122 人增加到 1,731 人（增加了 54%）。达格列净减少了门诊患者的需求单独强化利尿剂（HR 0.72；95% CI：0.64-0.82），以及作为心力衰竭或心血管死亡恶化的扩展复合终点的一部分进行分析时（HR 0.76；95% CI：0.69-0.84） <b>。</b>射血分数轻度降低或保留的心力衰竭，在门诊护理中需要口服利尿剂强化的心力衰竭恶化是常见的，预后不良，达格列净可显着减少这种情况。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37632455/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827060719&v=2.17.9.post6+86293ac">37632455</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066506>10.1161/CIRCULATIONAHA.123.066506</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37632455</guid><pubDate> Sat, 26 Aug 2023 06:00:00 -0400</pubDate><dc:creator>萨菲亚·查图尔</dc:creator><dc:creator>穆蒂亚·瓦杜加纳坦</dc:creator><dc:creator>——布莱恩·L·克拉吉特</dc:creator><dc:creator>——乔纳森·W·坎宁安</dc:creator><dc:creator>基兰·F·多彻蒂</dc:creator><dc:creator>Akshay S Desai更多</dc:creator><dc:creator>帕迪普·S·琼德</dc:creator><dc:creator>鲁道夫·德波尔</dc:creator><dc:creator>——阿德里安·F·埃尔南德斯</dc:creator><dc:creator>西尔维奥·因祖奇</dc:creator><dc:creator>米哈伊尔·N·科西博罗德</dc:creator><dc:creator>卡罗琳·SP·林</dc:creator><dc:creator>费利佩·马丁内斯</dc:creator><dc:creator>桑吉夫·J·沙阿</dc:creator><dc:creator>马格努斯·彼得森</dc:creator><dc:creator>安娜·玛丽亚·朗基尔德</dc:creator><dc:creator>约翰·JV·麦克默里</dc:creator><dc:creator>斯科特·D·所罗门</dc:creator><dc:date>2023-08-26</dc:date><dc:source>循环</dc:source><dc:title>DELIVER 试验中射血分数轻度降低和保留的心力衰竭患者的门诊病情恶化</dc:title><dc:identifier>下午：37632455</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.066506</dc:identifier></item><item><title>心力衰竭右心室起搏升级为心脏再同步治疗：一项随机试验</title><link/>https://pubmed.ncbi.nlm.nih.gov/37632437/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230827060719&amp;v=2.17.9.post6+86293ac<description>结论：在具有显着 RVP 负担和射血分数降低的起搏器或 ICD 患者中，与 ICD 治疗相比，升级至 CRT-D 降低了全因死亡率、心力衰竭住院或缺乏逆重构的综合风险。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 26 日：ehad591。doi：10.1093/eurheartj/ehad591。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：从头植入除颤器心脏再同步治疗（CRT-D）可降低左束支传导阻滞、心力衰竭和射血分数降低（HFrEF）患者的发病率和死亡率风险。起搏（RVP）， CRT-D升级不确定。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：在这项多中心、随机、对照试验中，360 名有症状（纽约心脏协会 II-IVa 级）HFrEF 患者佩戴起搏器或植入式心律转复除颤器 (ICD)，RVP 负荷高 ≥20%，且有宽阔的起搏 QRS 波群. 持续时间 ≥ 150 毫秒的患者以 3:2 的比例随机分配接受 CRT-D 升级 (n = 215) 或 ICD (n = 145)。主要结局是全因死亡率、心力衰竭住院或&lt; 12 个月时评估左心室收缩末期容积减少 15%。次要结果包括全因死亡率或心力衰竭住院治疗。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在中位随访 12.4 个月的时间里，CRT-D 组的主要结局发生率为 58/179 (32.4%)，而 ICD 组的主要结局发生率为 101/128 (78.9%) [比值比 0.11；95%置信区间 (CI) 0.06-0.19；p &lt; 0.001]。CRT-D 组的全因死亡率或心力衰竭住院率为 22/215 (10%)，而 ICD 组为 46/145 (32%) （风险比 0.27；95% CI 0.16-0.47；p &lt; 0.001）。/142 (7.8%)]。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在具有显着 RVP 负担和射血分数降低的起搏器或 ICD 患者中，与 ICD 治疗相比，升级至 CRT-D 降低了全因死亡率、心力衰竭住院或缺乏逆重构的综合风险。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37632437/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827060719&v=2.17.9.post6+86293ac">37632437</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad591>10.1093/eurheartj/ehad591</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37632437</guid><pubDate> Sat, 26 Aug 2023 06:00:00 -0400</pubDate><dc:creator>贝拉·默克利</dc:creator><dc:creator>罗伯特·哈塔拉</dc:creator><dc:creator>杰兹·K·瓦尼茨</dc:creator><dc:creator>加博·杜雷</dc:creator><dc:creator>恰巴·福尔德西</dc:creator><dc:creator>佐尔坦·索姆</dc:creator><dc:creator>玛丽安娜·内梅斯</dc:creator><dc:creator>金加·戈辛斯卡-比斯</dc:creator><dc:creator>拉斯洛·盖勒</dc:creator><dc:creator>恩德烈·齐玛</dc:creator><dc:creator>伊斯特万·奥斯海默</dc:creator><dc:creator>莱文特·莫纳尔</dc:creator><dc:creator>朱莉娅·卡拉迪</dc:creator><dc:creator>——格哈德·辛德里克斯</dc:creator><dc:creator>伊兰·戈登伯格</dc:creator><dc:creator>赫尔穆特·克莱因</dc:creator><dc:creator>马蒂亚斯·西盖蒂</dc:creator><dc:creator>斯科特·D·所罗门</dc:creator><dc:creator>瓦伦蒂娜·库蒂法</dc:creator><dc:creator>阿提拉·科瓦奇</dc:creator><dc:creator>安娜玛丽亚·科斯汀</dc:creator><dc:date>2023-08-26</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>心力衰竭右心室起搏升级为心脏再同步治疗：一项随机试验</dc:title><dc:identifier>下午：37632437</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad591</dc:identifier></item><item><title>布达佩斯试验：射血分数降低的心力衰竭升级的良好成绩</title><link/>https://pubmed.ncbi.nlm.nih.gov/37632436/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230827060719&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 26 日：ehad588。doi：10.1093/eurheartj/ehad588。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37632436/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827060719&v=2.17.9.post6+86293ac">37632436</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad588>10.1093/eurheartj/ehad588</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37632436</guid><pubDate> Sat, 26 Aug 2023 06:00:00 -0400</pubDate><dc:creator>塞西莉亚·林德</dc:creator><dc:date>2023-08-26</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>布达佩斯试验：射血分数降低的心力衰竭升级的良好成绩</dc:title><dc:identifier>下午：37632436</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad588</dc:identifier></item><item><title>羧基麦芽糖铁治疗缺铁性心力衰竭的疗效：个体患者数据荟萃分析</title><link/>https://pubmed.ncbi.nlm.nih.gov/37632415/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230827060719&amp;v=2.17.9.post6+86293ac<description>结论：在左心室射血分数降低的缺铁性心力衰竭患者中，静脉注射 FCM 可显着降低因心力衰竭和心血管原因入院的风险，但对死亡率没有明显影响。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 26 日：ehad586。doi：10.1093/eurheartj/ehad586。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：虽然静脉注射羧基麦芽糖铁 (FCM) 对缺铁 (ID) 和心力衰竭 (HF) 患者的症状和运动能力具有有益作用，但治疗对临床事件的影响仍然是研究的主题。这项荟萃分析旨在描述 FCM 治疗对住院率和死亡率的影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：对来自随机、安慰剂对照 FCM 试验的患者水平数据进行了分析，这些试验包括随访时间≥52 周的心衰和智力障碍成人患者。共同主要疗效终点为 (1) 总/复发性心血管住院和心血管死亡的复合终点. , 和 (2) 52 周内心衰住院总人数和心血管死亡的复合。关键次要终点包括各个复合终点成分。使用负二项式模型分析事件发生率。还检查了治疗中出现的不良事件。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：纳入了总共 4501 名患者的三项 FCM 试验。FCM 与共同主要终点 1 的风险显着降低相关（比率 [RR] 0.86；95% 置信区间 [CI] 0.75-0.98；P=0.029 Cochran Q：0.008），共同主要终点 2 有减少的趋势（RR 0.87；95% CI 0.75-1.01；P=0.076；Cochran Q：0.024）。治疗效果似乎是住院率降低的结果，而不是住院率降低的结果。提高生存率。治疗似乎具有良好的安全性且耐受性良好。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在左心室射血分数降低的缺铁性心力衰竭患者中，静脉注射 FCM 可显着降低因心力衰竭和心血管原因入院的风险，但对死亡率没有明显影响。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37632415/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827060719&v=2.17.9.post6+86293ac">37632415</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad586>10.1093/eurheartj/ehad586</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37632415</guid><pubDate> Sat, 26 Aug 2023 06:00:00 -0400</pubDate><dc:creator>彼得·波尼科夫斯基</dc:creator><dc:creator>——罗伯特·J·门茨</dc:creator><dc:creator>阿德里安·F·埃尔南德斯</dc:creator><dc:creator>贾维德·巴特勒</dc:creator><dc:creator>穆罕默德·沙泽布·汗更多</dc:creator><dc:creator>德克·J·范·维尔德豪森</dc:creator><dc:creator>伯纳德·鲁伯特</dc:creator><dc:creator>妮可·布莱克曼</dc:creator><dc:creator>蒂姆·弗里德</dc:creator><dc:creator>埃娃·扬科斯卡</dc:creator><dc:creator>斯特凡·D·安克</dc:creator><dc:date>2023-08-26</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>Efficacy of Ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis</dc:title><dc:identifier> pmid:37632415</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad586</dc:identifier></item><item><title> Plasma cholesterol levels in infancy: a neglected resource</title><link/> https://pubmed.ncbi.nlm.nih.gov/37632413/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230827060719&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 26:ehad558. doi: 10.1093/eurheartj/ehad558. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37632413/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827060719&v=2.17.9.post6+86293ac">37632413</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad558>10.1093/eurheartj/ehad558</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37632413</guid><pubDate> Sat, 26 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Kirsten B Holven</dc:creator><dc:date> 2023-08-26</dc:date><dc:source> European heart journal</dc:source><dc:title> Plasma cholesterol levels in infancy: a neglected resource</dc:title><dc:identifier> pmid:37632413</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad558</dc:identifier></item><item><title> Significance of lipids, lipoproteins, and apolipoproteins during the first 14-16 months of life</title><link/> https://pubmed.ncbi.nlm.nih.gov/37632410/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230827060719&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Lipid parameters changed during the first 14-16 months of life, and sex, gestational age, birth weight, breastfeeding, and high parental concentrations influenced concentrations. Children with high concentrations of atherogenic lipid traits at birth had higher concentrations at 2 and 14-16 months. These findings increase our knowledge of how lipid traits develop over the first 14-16 months of life and may help in deciding the optimal child age for universal familial... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 26:ehad547. doi: 10.1093/eurheartj/ehad547. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND AND AIMS: The aims of this study were to investigate lipid parameters during the first 14-16 months of life, to identify influential factors, and to test whether high concentrations at birth predict high concentrations at 2- and 14-16 months. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: The Copenhagen Baby Heart Study, including 13,354 umbilical cord blood samples and parallel venous blood samples from children and parents at birth (n = 444), 2 months (n = 364), and 14-16 months (n = 168), was used. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Concentrations of lipids, lipoproteins, and apolipoproteins in umbilical cord blood samples correlated highly with venous blood samples from newborns. Concentrations of low-density lipoprotein (LDL) cholesterol, non-high-density lipoprotein (HDL) cholesterol, apolipoprotein B, and lipoprotein(a) increased stepwise from birth to 2 months to 14-16 months. Linear mixed models showed that concentrations of LDL cholesterol, non-HDL cholesterol, and lipoprotein(a) above the 80th percentile at birth were associated with significantly higher concentrations at 2 and 14-16 months. Finally, lipid concentrations differed according to sex, gestational age, birth weight, breastfeeding, and parental lipid concentrations. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Lipid parameters changed during the first 14-16 months of life, and sex, gestational age, birth weight, breastfeeding, and high parental concentrations influenced concentrations. Children with high concentrations of atherogenic lipid traits at birth had higher concentrations at 2 and 14-16 months. These findings increase our knowledge of how lipid traits develop over the first 14-16 months of life and may help in deciding the optimal child age for universal familial hypercholesterolaemia screening.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37632410/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827060719&v=2.17.9.post6+86293ac">37632410</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad547>10.1093/eurheartj/ehad547</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37632410</guid><pubDate> Sat, 26 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Sofie Taageby Nielsen</dc:creator><dc:creator> Rikke Mohr Lytsen</dc:creator><dc:creator> Nina Strandkjær</dc:creator><dc:creator> Ida Juul Rasmussen</dc:creator><dc:creator> Anne-Sophie Sillesen</dc:creator><dc:creator> R Ottilia B Vøgg</dc:creator><dc:creator> Anna Axelsson Raja</dc:creator><dc:creator> Børge G Nordestgaard</dc:creator><dc:creator> Pia R Kamstrup</dc:creator><dc:creator> Kasper Iversen</dc:creator><dc:creator> Henning Bundgaard</dc:creator><dc:creator> Anne Tybjærg-Hansen</dc:creator><dc:creator> Ruth Frikke-Schmidt</dc:creator><dc:date> 2023-08-26</dc:date><dc:source> European heart journal</dc:source><dc:title> Significance of lipids, lipoproteins, and apolipoproteins during the first 14-16 months of life</dc:title><dc:identifier> pmid:37632410</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad547</dc:identifier></item><item><title> High Costs of Cardiovascular Disease in the European Union</title><link/> https://pubmed.ncbi.nlm.nih.gov/37632364/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230827060719&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 26:ehad587. doi: 10.1093/eurheartj/ehad587. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37632364/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827060719&v=2.17.9.post6+86293ac">37632364</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad587>10.1093/eurheartj/ehad587</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37632364</guid><pubDate> Sat, 26 Aug 2023 06:00:00 -0400</pubDate><dc:creator> William S Weintraub</dc:creator><dc:date> 2023-08-26</dc:date><dc:source> European heart journal</dc:source><dc:title> High Costs of Cardiovascular Disease in the European Union</dc:title><dc:identifier> pmid:37632364</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad587</dc:identifier></item><item><title> Economic burden of cardiovascular diseases in the European Union: a population-based cost study</title><link/> https://pubmed.ncbi.nlm.nih.gov/37632363/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230827060719&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: This study provides contemporary estimates of the wide-ranging impact of CVD on all aspects of the economy. The data help inform evidence-based policies to reduce the impact of CVD, promoting care access and better health outcomes and economic sustainability. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 26:ehad583. doi: 10.1093/eurheartj/ehad583. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND AND AIMS: Cardiovascular disease (CVD) impacts significantly health and social care systems as well as society through premature mortality and disability, with patients requiring care from relatives. Previous pan- European estimates of the economic burden of CVD are now outdated. This study aims to provide novel, up-to-date evidence on the economic burden across the 27 European Union (EU) countries in 2021. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Aggregate country-specific resource use data on morbidity, mortality, and health, social and informal care were obtained from international sources, such as the Statistical Office of the European Communities, enhanced by data from the European Society of Cardiology Atlas programme and patient-level data from the Survey of Health, Ageing and Retirement in Europe. Country-specific unit costs were used, with cost estimates reported on a per capita basis, after adjustment for price differentials. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: CVD is estimated to cost the EU €282 billion annually, with health and long-term care accounting for €155 billion (55%), equalling 11% of EU-health expenditure. Productivity losses accounted for 17% (€48 billion), whereas informal care costs were €79 billion (28%). CVD represented a cost of €630 per person, ranging from €381 in Cyprus to €903 in Germany. Coronary heart disease accounted for 27% (€77 billion) and cerebrovascular diseases for 27% (€76 billion) of CVD costs. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: This study provides contemporary estimates of the wide-ranging impact of CVD on all aspects of the economy. The data help inform evidence-based policies to reduce the impact of CVD, promoting care access and better health outcomes and economic sustainability.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37632363/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827060719&v=2.17.9.post6+86293ac">37632363</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad583>10.1093/eurheartj/ehad583</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37632363</guid><pubDate> Sat, 26 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Ramon Luengo-Fernandez</dc:creator><dc:creator> Marjan Walli-Attaei</dc:creator><dc:creator> Alastair Gray</dc:creator><dc:creator> Aleksandra Torbica</dc:creator><dc:creator> Aldo P Maggioni</dc:creator><dc:creator> Radu Huculeci</dc:creator><dc:creator> Firoozeh Bairami</dc:creator><dc:creator> Victor Aboyans</dc:creator><dc:creator> Adam D Timmis</dc:creator><dc:creator> Panos Vardas</dc:creator><dc:creator> Jose Leal</dc:creator><dc:date> 2023-08-26</dc:date><dc:source> European heart journal</dc:source><dc:title> Economic burden of cardiovascular diseases in the European Union: a population-based cost study</dc:title><dc:identifier> pmid:37632363</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad583</dc:identifier></item><item><title> Interatrial shunt devices for heart failure</title><link/> https://pubmed.ncbi.nlm.nih.gov/37626203/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230827060719&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol. 2023 Aug 25. doi: 10.1038/s41569-023-00923-w. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37626203/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827060719&v=2.17.9.post6+86293ac">37626203</a> | DOI: <a href=https://doi.org/10.1038/s41569-023-00923-w>10.1038/s41569-023-00923-w</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37626203</guid><pubDate> Fri, 25 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Finn Gustafsson</dc:creator><dc:date> 2023-08-25</dc:date><dc:source> Nature reviews. Cardiology</dc:source><dc:title> Interatrial shunt devices for heart failure</dc:title><dc:identifier> pmid:37626203</dc:identifier><dc:identifier> doi:10.1038/s41569-023-00923-w</dc:identifier></item><item><title> Atrial fibrillation progression after cryoablation versus radiofrequency ablation: the CIRCA-DOSE trial</title><link/> https://pubmed.ncbi.nlm.nih.gov/37624879/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230827060719&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Catheter ablation of paroxysmal AF using radiofrequency energy was associated with fewer patients developing persistent AF on follow-up. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 25:ehad572. doi: 10.1093/eurheartj/ehad572. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND AND AIMS: Atrial fibrillation (AF) is a chronic, progressive disorder. Persistent forms of AF are associated with increased rates of thromboembolism, heart failure, and death. Catheter ablation modifies the pathogenic mechanism of AF progression. No randomized studies have evaluated the impact of the ablation energy on progression to persistent atrial tachyarrhythmia. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: 346 patients with drug-refractory paroxysmal AF were enrolled and randomized to contact-force guided radiofrequency ablation (CF-RF ablation, n = 115), 4-minute cryoballoon ablation (CRYO-4, n = 115), or 2-minute cryoballoon ablation (CRYO-2, n = 116). Implantable cardiac monitors placed at study entry were used for follow-up. The main outcome was the first episode of persistent atrial tachyarrhythmia. Secondary outcomes included atrial tachyarrhythmia recurrence, and arrhythmia burden on implantable monitor. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: At a median of 944.0 (interquartile range [IQR], 612.5-1104) days, 0 of 115 patients (0.0%) randomly assigned to CF-RF, 8 of 115 patients (7.0%) assigned to CRYO-4, and 5 of 116 patients (4.3%) assigned to CRYO-2 experienced an episode of persistent atrial tachyarrhythmia (P = 0.03). A documented recurrence of any atrial tachyarrhythmia ≥30 seconds occurred in 56.5%, 53.9%, and 62.9% of those randomised to CF-RF, CRYO-4, and CRYO-2, respectively (P = 0.65). Compared to the pre-ablation monitoring period, AF burden was reduced by a median of 99.5% (IQR 94.0-100.0%) with CF-RF, 99.9% (IQR 93.3-100.0%) with CRYO-4, and 99.1% (IQR 87.0-100.0%) with CRYO-2 (P = 0.38). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Catheter ablation of paroxysmal AF using radiofrequency energy was associated with fewer patients developing persistent AF on follow-up.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37624879/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827060719&v=2.17.9.post6+86293ac">37624879</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad572>10.1093/eurheartj/ehad572</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37624879</guid><pubDate> Fri, 25 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Jason G Andrade</dc:creator><dc:creator> Marc W Deyell</dc:creator><dc:creator> Paul Khairy</dc:creator><dc:creator> Jean Champagne</dc:creator><dc:creator> Peter Leong-Sit</dc:creator><dc:creator> Paul Novak</dc:creator><dc:creator> Lawrence Sterns</dc:creator><dc:creator> Jean-Francois Roux</dc:creator><dc:creator> John Sapp</dc:creator><dc:creator> Richard Bennett</dc:creator><dc:creator> Matthew Bennett</dc:creator><dc:creator> Nathaniel Hawkins</dc:creator><dc:creator> Prashanthan Sanders</dc:creator><dc:creator> Laurent Macle</dc:creator><dc:creator> CIRCA-DOSE Study Investigators</dc:creator><dc:date> 2023-08-25</dc:date><dc:source> European heart journal</dc:source><dc:title> Atrial fibrillation progression after cryoablation versus radiofrequency ablation: the CIRCA-DOSE trial</dc:title><dc:identifier> pmid:37624879</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad572</dc:identifier></item><item><title> TRI-SCORE and benefit of intervention in patients with severe tricuspid regurgitation</title><link/> https://pubmed.ncbi.nlm.nih.gov/37624856/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230827060719&amp;v=2.17.9.post6+86293ac<description> CONCLUSION: Survival progressively decreased with the TRI-SCORE irrespective of treatment modality. Compared to conservative management, an early and successful surgical or transcatheter intervention improved 2-year survival in patients at low and, to a lower extent, intermediate TRI-SCORE, while no benefit was observed in the high TRI-SCORE category. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 25:ehad585. doi: 10.1093/eurheartj/ehad585. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND AND AIMS: Benefit of tricuspid regurgitation (TR) correction and timing of intervention are unclear. This study aimed to compare survival rates after surgical or transcatheter intervention to conservative management according to TR clinical stage as assessed using the TRI-SCORE. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: 2,413 patients with severe isolated functional TR were enrolled in TRIGISTRY (1217 conservatively managed, 551 isolated tricuspid valve surgery and 645 transcatheter valve repair). The primary endpoint was survival at 2 years. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: The TRI-SCORE was low (≤3) in 32%, intermediate (4-5) in 33% and high (≥6) in 35%. A successful correction was achieved in 97% and 65% of patients in the surgical and transcatheter groups, respectively. Survival rates decreased with the TRI-SCORE in the three treatment groups (all P &lt; 0.0001). In the low TRI-SCORE category, survival rates were higher in the surgical and transcatheter groups than in the conservative management group (93%, 87% and 79%, respectively; P = 0.0002). In the intermediate category, no significant difference between groups was observed overall (80%, 71% and 71%, respectively; P = 0.13) but benefit of the intervention became significant when the analysis was restricted to patients with successful correction (80%, 81% and 71%, respectively; P = 0.009). In the high TRI-SCORE category, survival was similar between groups even when restricted to patients with successful correction (61%, 68% and 58% respectively, P = 0.08). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSION: Survival progressively decreased with the TRI-SCORE irrespective of treatment modality. Compared to conservative management, an early and successful surgical or transcatheter intervention improved 2-year survival in patients at low and, to a lower extent, intermediate TRI-SCORE, while no benefit was observed in the high TRI-SCORE category.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37624856/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827060719&v=2.17.9.post6+86293ac">37624856</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad585>10.1093/eurheartj/ehad585</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37624856</guid><pubDate> Fri, 25 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Julien Dreyfus</dc:creator><dc:creator> Xavier Galloo</dc:creator><dc:creator> Maurizio Taramasso</dc:creator><dc:creator> Gregor Heitzinger</dc:creator><dc:creator> Giovanni Benfari</dc:creator><dc:creator> Karl-Patrick Kresoja</dc:creator><dc:creator> Fernando Juarez-Casso</dc:creator><dc:creator> Hazem Omran</dc:creator><dc:creator> Yohann Bohbot</dc:creator><dc:creator> Christos Iliadis</dc:creator><dc:creator> Giulio Russo</dc:creator><dc:creator> Yan Topilsky</dc:creator><dc:creator> Marcel Weber</dc:creator><dc:creator> Luis Nombela-Franco</dc:creator><dc:creator> Alessandra Sala</dc:creator><dc:creator> Andrea Eixerés-Esteve</dc:creator><dc:creator> Bernard Iung</dc:creator><dc:creator> Jean-François Obadia</dc:creator><dc:creator> Rodrigo Estevez Loureiro</dc:creator><dc:creator> Elisabeth Riant</dc:creator><dc:creator> Erwan Donal</dc:creator><dc:creator> Jörg Hausleiter</dc:creator><dc:creator> Luigi Badano</dc:creator><dc:creator> Thierry Le Tourneau</dc:creator><dc:creator> Augustin Coisne</dc:creator><dc:creator> Thomas Modine</dc:creator><dc:creator> Azeem Latib</dc:creator><dc:creator> Fabien Praz</dc:creator><dc:creator> Stephan Windecker</dc:creator><dc:creator> Jose Luis Zamorano</dc:creator><dc:creator> Ralph Stephan von Bardeleben</dc:creator><dc:creator> Gilbert HL Tang</dc:creator><dc:creator> Rebecca Hahn</dc:creator><dc:creator> John Webb</dc:creator><dc:creator> Denisa Muraru</dc:creator><dc:creator> Mohammed Nejjari</dc:creator><dc:creator> Vincent Chan</dc:creator><dc:creator> Michele De Bonis</dc:creator><dc:creator> Manuel Carnero-Alcazar</dc:creator><dc:creator> Georg Nickenig</dc:creator><dc:creator> Roman Pfister</dc:creator><dc:creator> Christophe Tribouilloy</dc:creator><dc:creator> Volker Rudolph</dc:creator><dc:creator> Juan Crestanello</dc:creator><dc:creator> Philipp Lurz</dc:creator><dc:creator> Philipp Bartko</dc:creator><dc:creator> Francesco Maisano</dc:creator><dc:creator> Jeroen Bax</dc:creator><dc:creator> Maurice Enriquez-Sarano</dc:creator><dc:creator> David Messika-Zeitoun</dc:creator><dc:creator> TRIGISTRY investigators</dc:creator><dc:date> 2023-08-25</dc:date><dc:source> European heart journal</dc:source><dc:title> TRI-SCORE and benefit of intervention in patients with severe tricuspid regurgitation</dc:title><dc:identifier> pmid:37624856</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad585</dc:identifier></item><item><title> Adverse outcomes in patients with atrial fibrillation: how previous successes can unmask new challenges</title><link/> https://pubmed.ncbi.nlm.nih.gov/37624615/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230827060719&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 25:ehad575. doi: 10.1093/eurheartj/ehad575. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37624615/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827060719&v=2.17.9.post6+86293ac">37624615</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad575>10.1093/eurheartj/ehad575</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37624615</guid><pubDate> Fri, 25 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Pascal B Meyre</dc:creator><dc:creator> David Conen</dc:creator><dc:date> 2023-08-25</dc:date><dc:source> European heart journal</dc:source><dc:title> Adverse outcomes in patients with atrial fibrillation: how previous successes can unmask new challenges</dc:title><dc:identifier> pmid:37624615</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad575</dc:identifier></item><item><title> Temporal trends of cause-specific mortality after diagnosis of atrial fibrillation</title><link/> https://pubmed.ncbi.nlm.nih.gov/37624589/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230827060719&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: After AF diagnosis, cardio/cerebrovascular mortality and hospitalisation has declined, whilst hospitalisation for non-cardio/cerebrovascular disease has increased. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 25:ehad571. doi: 10.1093/eurheartj/ehad571. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND AND AIMS: Reports of outcomes after atrial fibrillation (AF) diagnosis are conflicting. The aim of this study was to investigate mortality and hospitalisation rates following AF diagnosis over time, by cause, and by patient features. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Individuals aged ≥16 years with a first diagnosis of AF were identified from the UK Clinical Practice Research Datalink-GOLD dataset from Jan 1, 2001 to Dec 31, 2017. The primary outcomes were all-cause and cause-specific mortality and hospitalisation at 1 year following diagnosis. Poisson regression was used to calculate rate ratios (RRs) for mortality and incidence rate ratios (IRRs) for hospitalisation and 95% confidence intervals (CIs) comparing 2001/02 and 2016/17, adjusted for age, sex, region, socioeconomic status and 18 major comorbidities. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Of 72 412 participants, mean (SD) age was 75.6 (12.4) years and 44 762 (61.8%) had ≥3 comorbidities. All-cause mortality declined (RR 2016/17 vs 2001/02 0.72; 95% CI 0.65-0.80), with large declines for cardiovascular (RR 0.46; 95% CI 0.37-0.58) and cerebrovascular mortality (RR 0.41; 95% CI 0.29-0.60) but not for non-cardio/cerebrovascular causes of death (RR 0.91; 95% CI 0.80-1.04). By 2016/17 deaths from dementia (67, 8.0%), outstripped deaths from acute myocardial infarction, heart failure and acute stroke combined (56, 6.7%, p &lt; 0.001). Overall hospitalisation rates increased (IRR 2016/17 vs 2001/02 1.17; 95% CI, 1.13-1.22), especially for non-cardio/cerebrovascular causes (IRR 1.42; 95% CI 1.39-1.45). Older, more deprived, and hospital-diagnosed AF patients experienced higher event rates. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: After AF diagnosis, cardio/cerebrovascular mortality and hospitalisation has declined, whilst hospitalisation for non-cardio/cerebrovascular disease has increased.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37624589/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230827060719&v=2.17.9.post6+86293ac">37624589</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad571>10.1093/eurheartj/ehad571</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37624589</guid><pubDate> Fri, 25 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Jianhua Wu</dc:creator><dc:creator> Ramesh Nadarajah</dc:creator><dc:creator> Yoko M Nakao</dc:creator><dc:creator> Kazuhiro Nakao</dc:creator><dc:creator> Chris Wilkinson</dc:creator><dc:creator> J Campbell Cowan</dc:creator><dc:creator> A John Camm</dc:creator><dc:creator> Chris P Gale</dc:creator><dc:date> 2023-08-25</dc:date><dc:source> European heart journal</dc:source><dc:title> Temporal trends of cause-specific mortality after diagnosis of atrial fibrillation</dc:title><dc:identifier> pmid:37624589</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad571</dc:identifier></item></channel></rss>